A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC)

Mitchell L Ramsey, Janet Nuttall, Phil A Hart, TACTIC Investigative Team, Mitchell L Ramsey, Janet Nuttall, Phil A Hart, TACTIC Investigative Team

Abstract

Background: Chronic pancreatitis (CP) is a progressive, fibro-inflammatory disease characterized by enzymatic autoactivation and subsequent fibrotic replacement of acinar cells. A significant proportion of patients develop pain, which may be due to many causes, including perineural inflammation, altered central processing of pain signals, parenchymal structural changes, and ductal obstruction. Currently there are no approved medical treatment options for CP-associated pain. NI-03 (camostat mesilate) is an orally administered serine protease inhibitor that reduces pancreatic enzyme activity and has been widely used for the treatment of CP-associated pain in Japan. The current study will assess the safety and efficacy of NI-03 for reduction of CP-associated pain in the USA.

Methods: The current study consists of two phases. First, a phase I study will be performed to establish the pharmacokinetics and safety profile over a 1-week period following a single dose (100, 200, or 300 mg). Subsequently, a phase II study will be performed consisting of a double-blind, randomized, controlled trial (RCT). This RCT will evaluate the efficacy of each of the three doses of NI-03 given three times daily compared to placebo over 28 days. A 7-day, single-blind, run-in period will precede the double-blind phase to assess baseline pain characteristics. The primary efficacy outcome is the average of worst daily pain scores (numeric rating scale of 0-10) over the terminal 7 days of the study period compared to baseline. Secondary efficacy outcomes include change in opioid dose and quality of life measures, and time to first rescue intravenous analgesic. Adverse events will be recorded.

Discussion: NI-03 has been used successfully and safely in Japan to treat CP-associated pain. The aim of the current study is to assess the safety and efficacy of NI-03 using a rigorous RCT in a population in the USA. This study may fill an important clinical gap to provide an effective medical treatment option for CP-associated pain.

Trial registration: ClinicalTrials.gov, NCT02693093 . Registered through the National Institutes of Health on 26 February 2016.

Keywords: Abdominal pain; Camostat; Pancreatic diseases; Serine protease inhibitor.

Conflict of interest statement

MR has no disclosures.

JN is employed by Kangen Pharmaceuticals America, LLC.

PH has served as a consultant for Abbvie, Inc. and Kangen Pharmaceuticals America, LLC (formerly KC Specialty Therapeutics, LLC).

Figures

Fig. 1
Fig. 1
Standard protocol items: recommendation for interventional trials (SPIRIT) figure demonstrating the study timeline for the randomized, double-blind trial of NI-03 for pain control among subjects with painful chronic pancreatitis. BPI, Brief Pain Inventory; PANQOLI, Pancreatitis Quality of Life Instrument; TID, three times per day; EKG, electrocardiogram

References

    1. Whitcomb DC, et al. Chronic pancreatitis: an international draft consensus proposal for a new mechanistic definition. Pancreatology. 2016;16:218–224. doi: 10.1016/j.pan.2016.02.001.
    1. Ramsey ML, Conwell DL, Hart PA. Complications of chronic pancreatitis. Dig Dis Sci. 2017;62:1745–1750. doi: 10.1007/s10620-017-4518-x.
    1. Braganza JM, Dormandy TL. Micronutrient therapy for chronic pancreatitis: rationale and impact. JOP. 2010;11:99–112.
    1. Siriwardena AK, et al. Antioxidant therapy does not reduce pain in patients with chronic pancreatitis: the ANTICIPATE study. Gastroenterology. 2012;143:655–663.e651. doi: 10.1053/j.gastro.2012.05.046.
    1. Bhardwaj P, et al. A randomized controlled trial of antioxidant supplementation for pain relief in patients with chronic pancreatitis. Gastroenterology. 2009;136:149–159.e142. doi: 10.1053/j.gastro.2008.09.028.
    1. Uden S, et al. Antioxidant therapy for recurrent pancreatitis: placebo-controlled trial. Aliment Pharmacol Ther. 1990;4:357–371. doi: 10.1111/j.1365-2036.1990.tb00482.x.
    1. Olesen SS, et al. Randomised clinical trial: pregabalin attenuates experimental visceral pain through sub-cortical mechanisms in patients with painful chronic pancreatitis. Aliment Pharmacol Ther. 2011;34:878–887. doi: 10.1111/j.1365-2036.2011.04802.x.
    1. Drug interview form: Foipan® tablets 100mg . Prepared in accordance with the IF Guidelines of the Japanese Society of Hospital Pharmacists. 2009. pp. 16–17.
    1. Ohshio G, et al. Esterase inhibitors prevent lysosomal enzyme redistribution in two noninvasive models of experimental pancreatitis. Gastroenterology. 1989;96:853–859. doi: 10.1016/0016-5085(89)90912-8.
    1. Obata T, et al. Effect of FOY-305 on the kinin-forming systems. New Horiz Med. 1980;12:19.
    1. Abe M, et al. Use of FOY-305 for the treatment of pain attacks associated with chronic pancreatitis. New Horiz Med. 1980;12:233.
    1. Kubota Y, Maeda S. Experience with FOY-305 in patients with pancreatitis. New Horiz Med. 1980;12:211.
    1. Ishii K, et al. Evaluation of the efficacy of FOY-305 in chronic pancreatitis: multicenter, double-blind, parallel-group study. New Horiz Med. 1984;16:844.
    1. Ishii K, et al. Evaluation of the efficacy of FOY-305 in pancreatitis: multicenter, double-blind study. New Horiz Med. 1980;12:261.
    1. Hirono T. Clinical experience with oral anti-enzyme agent FOY-305 for pancreatitis. New Horiz Med. 1980;12:215.
    1. Fujiwara S, et al. Clinical experience with oral FOY-305 for pancreatitis. New Horiz Med. 1980;12:104.
    1. Hirayama A, et al. Clinical analysis of FOY-305 for pancreatitis: a small double-blind clinical trial. New Horiz Med. 1980;12:253.
    1. Hirayama A, et al. Clinical investigation of FOY-305 against pancreatitis. New Horiz Med. 1980;12:245.
    1. Horiguchi Y, Nakajima S, Ito M. Clinical experience with FOY-305 for pancreatitis. New Horiz Med. 1980;12:227.
    1. Kinami Y, et al. Clinical effect of FOY-305 on pancreatitis. New Horiz Med. 1980;12:108.
    1. Tanaka N, Rsuchiya R. Clinical efficacy of FOY-305 in pancreatitis. New Horiz Med. 1980;12:223.
    1. Catalano MF, et al. EUS-based criteria for the diagnosis of chronic pancreatitis: the Rosemont classification. Gastrointest Endosc. 2009;69:1251–1261. doi: 10.1016/j.gie.2008.07.043.
    1. Conwell DL, et al. American Pancreatic Association practice guidelines in chronic pancreatitis: evidence-based report on diagnostic guidelines. Pancreas. 2014;43:1143–1162. doi: 10.1097/MPA.0000000000000237.
    1. Anaizi A, Hart PA, Conwell DL. Diagnosing chronic pancreatitis. Dig Dis Sci. 2017;62:1713–1720. doi: 10.1007/s10620-017-4493-2.
    1. Shimosegawa T, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40:352–358. doi: 10.1097/MPA.0b013e3182142fd2.
    1. Wassef W, et al. Pancreatitis Quality of Life Instrument: a psychometric evaluation. Am J Gastroenterol. 2016;111:1177–1186. doi: 10.1038/ajg.2016.225.
    1. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap. 1994;23:129–138.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner